Cargando…

Ocular Manifestations of Biopsy-Proven Pulmonary Sarcoidosis in Korea

PURPOSE: To investigate the clinical features and ocular manifestations of biopsy-proven pulmonary sarcoidosis in Korea. METHODS: 55 patients diagnosed with pulmonary sarcoidosis by bronchoscopic or excisional biopsy were included. By retrospective clinical chart review, we investigated features of...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Seung Yong, Lee, Jae Hoon, Won, Jae-Yon, Shin, Jeong Ah, Park, Young-Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896406/
https://www.ncbi.nlm.nih.gov/pubmed/29785303
http://dx.doi.org/10.1155/2018/9308414
_version_ 1783313835997790208
author Choi, Seung Yong
Lee, Jae Hoon
Won, Jae-Yon
Shin, Jeong Ah
Park, Young-Hoon
author_facet Choi, Seung Yong
Lee, Jae Hoon
Won, Jae-Yon
Shin, Jeong Ah
Park, Young-Hoon
author_sort Choi, Seung Yong
collection PubMed
description PURPOSE: To investigate the clinical features and ocular manifestations of biopsy-proven pulmonary sarcoidosis in Korea. METHODS: 55 patients diagnosed with pulmonary sarcoidosis by bronchoscopic or excisional biopsy were included. By retrospective clinical chart review, we investigated features of uveitis, ocular and systemic treatments, visual acuity, angiotensin-converting enzyme level, chest radiography, and pulmonary function tests. Clinical features were analyzed by presence of uveitis, site of biopsy, and first manifested sign of sarcoidosis. RESULTS: The group with uveitis (n = 39) presented with higher systemic (71.8%) and immunosuppressive treatment rates (35.9%) than the group without uveitis (31.3%, 0%, resp.) (P = 0.007, P = 0.005, resp.). There were no significant differences in clinical features, including systemic treatment rate, by type of biopsy. Of 39 patients with uveitis, the group with ocular manifestation as a first sign of sarcoidosis showed higher systemic and immunosuppressive treatment rates (88.9%, 55.6%) compared to the group with pulmonary manifestation as a first sign (57.1%, 19.0%) (P = 0.037, P = 0.018, resp.). CONCLUSIONS: In patients with biopsy-proven pulmonary sarcoidosis, the presence of ocular involvement and uveitis as a first sign could be significant factors associated with higher systemic treatment rate, especially with immunosuppressive agents. Biopsy site determined by location and size had no influence on clinical features.
format Online
Article
Text
id pubmed-5896406
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-58964062018-05-21 Ocular Manifestations of Biopsy-Proven Pulmonary Sarcoidosis in Korea Choi, Seung Yong Lee, Jae Hoon Won, Jae-Yon Shin, Jeong Ah Park, Young-Hoon J Ophthalmol Research Article PURPOSE: To investigate the clinical features and ocular manifestations of biopsy-proven pulmonary sarcoidosis in Korea. METHODS: 55 patients diagnosed with pulmonary sarcoidosis by bronchoscopic or excisional biopsy were included. By retrospective clinical chart review, we investigated features of uveitis, ocular and systemic treatments, visual acuity, angiotensin-converting enzyme level, chest radiography, and pulmonary function tests. Clinical features were analyzed by presence of uveitis, site of biopsy, and first manifested sign of sarcoidosis. RESULTS: The group with uveitis (n = 39) presented with higher systemic (71.8%) and immunosuppressive treatment rates (35.9%) than the group without uveitis (31.3%, 0%, resp.) (P = 0.007, P = 0.005, resp.). There were no significant differences in clinical features, including systemic treatment rate, by type of biopsy. Of 39 patients with uveitis, the group with ocular manifestation as a first sign of sarcoidosis showed higher systemic and immunosuppressive treatment rates (88.9%, 55.6%) compared to the group with pulmonary manifestation as a first sign (57.1%, 19.0%) (P = 0.037, P = 0.018, resp.). CONCLUSIONS: In patients with biopsy-proven pulmonary sarcoidosis, the presence of ocular involvement and uveitis as a first sign could be significant factors associated with higher systemic treatment rate, especially with immunosuppressive agents. Biopsy site determined by location and size had no influence on clinical features. Hindawi 2018-02-11 /pmc/articles/PMC5896406/ /pubmed/29785303 http://dx.doi.org/10.1155/2018/9308414 Text en Copyright © 2018 Seung Yong Choi et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Choi, Seung Yong
Lee, Jae Hoon
Won, Jae-Yon
Shin, Jeong Ah
Park, Young-Hoon
Ocular Manifestations of Biopsy-Proven Pulmonary Sarcoidosis in Korea
title Ocular Manifestations of Biopsy-Proven Pulmonary Sarcoidosis in Korea
title_full Ocular Manifestations of Biopsy-Proven Pulmonary Sarcoidosis in Korea
title_fullStr Ocular Manifestations of Biopsy-Proven Pulmonary Sarcoidosis in Korea
title_full_unstemmed Ocular Manifestations of Biopsy-Proven Pulmonary Sarcoidosis in Korea
title_short Ocular Manifestations of Biopsy-Proven Pulmonary Sarcoidosis in Korea
title_sort ocular manifestations of biopsy-proven pulmonary sarcoidosis in korea
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896406/
https://www.ncbi.nlm.nih.gov/pubmed/29785303
http://dx.doi.org/10.1155/2018/9308414
work_keys_str_mv AT choiseungyong ocularmanifestationsofbiopsyprovenpulmonarysarcoidosisinkorea
AT leejaehoon ocularmanifestationsofbiopsyprovenpulmonarysarcoidosisinkorea
AT wonjaeyon ocularmanifestationsofbiopsyprovenpulmonarysarcoidosisinkorea
AT shinjeongah ocularmanifestationsofbiopsyprovenpulmonarysarcoidosisinkorea
AT parkyounghoon ocularmanifestationsofbiopsyprovenpulmonarysarcoidosisinkorea